ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CLVS Description — Clovis Oncology Inc

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. Co.'s commercial product Rubraca™ (rucaparib) is a monotherapy for the treatment of patients with deleterious breast cancer (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated ovarian cancer. Co.'s other products include: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor.

Company Name:  Clovis Oncology Inc
Website:  www.clovisoncology.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CLVS:  24
Total Market Value Held by ETFs:  $245,081,644
Total Market Capitalization:  $3,056,000,000
% of Market Cap. Held by ETFs:  8.02%
 ETF   CLVS Weight   CLVS Amount 
 XBI   1.80%   $75,256,418         
 IWM   0.13%   $62,471,336         
 IBB   0.45%   $43,974,265         
 IWO   0.26%   $24,952,195         
 VBR   0.08%   $10,419,167         
 VBK   0.11%   $7,614,189         
 VHT   0.08%   $6,473,946         
 VXF   0.09%   $4,836,843         
 VTWO   0.15%   $2,451,282         
 IYH   0.09%   $1,915,002         
List of all 24 ETFs holding CLVS »
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
Warren Buffett Dividend Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
Top 10 Analyst Rated Consumer Stocks
Top 10 Analyst Rated Dividend Stocks
Top 10 Analyst Rated Energy Stocks
Top 10 Analyst Rated Financial Stocks
Top 10 Analyst Rated Healthcare Stocks
Top 10 Analyst Rated REIT Stocks
Top 10 Analyst Rated Technology Stocks
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Buy (3.29 out of 4)
57th percentile
(ranked higher than approx. 57% of all stocks covered)

Analysts Forecast:
CLVS Price Target

Based on data provided by Zacks Investment Research via Quandl.com


PARTNER NEWS:

Mon, Dec 11, 9:36 AM, Zacks
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

Wed, Dec 6, 2:09 PM, Zacks
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
The FDA grants priority review to Clovis (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

ETFs Holding CLVS | Clovis Oncology Inc | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2017, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.